15 results on '"Rauw J"'
Search Results
2. L'hydrologie, une partenaire de la géomorphopédologie pour une gestion transéchelle des grands enjeux environnementaux
- Author
-
Colard, F., Sohier, C., Degré, A., Rauw, J., Bauwens, A., Kummert, N., and Beckers, E.
- Subjects
Hydrology ,géomorphology ,soil sciences ,water-soil-plant relationships ,erosion ,nitrate ,simulation models ,Belgium ,Biotechnology ,TP248.13-248.65 ,Environmental sciences ,GE1-350 - Abstract
Hydrology: a partner of geomorphopedology in the scope of a scale-through environmental management. Unsaturated soil and subsoil are often called "critical zone" considering their major interfacing role in our environment. Dealing with solute transfer or water and soil conservation, hydrologic research relies on pedologic descriptions. It is the case from micro to macro scale analysis. Hydrodynamic parameters are derived from pedologic information on soil. They allow hydrologists to quantify and spatially describe the dynamic exchanges between water, soil, crops and atmosphere. The modelling of water and solute transfer through soil and vadose zone also needs them. The paper presents some research highlights on soil behaviour, hydrological modelling and forecasting under climate change. Erosion is another major topic. Soil is a poorly renewable resource. Soil conservation and soft hydraulic management in watersheds deserve more attention. They can help limiting nutrient and sediment transfer to surface water. Again, pedologic information is the starting point of conceptualization and modelling. Furthermore, the Soil Map of Belgium includes information on geomorphology and landscape descriptions which date from decades. They are of first importance to calibrate and validate detachment, transport and sedimentation models. In the current context of high environmental concern, it is demonstrated how hydrology and pedology have to be partners in order to deal with such major issues.
- Published
- 2011
3. Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis
- Author
-
Rauw, J., Wells, R.A., Chesney, A., Reis, M., Zhang, Liying, and Buckstein, Rena
- Published
- 2011
- Full Text
- View/download PDF
4. Cancer referral and treatment activity 2010&ndash
- Author
-
Savage, P., Holloway, C., Lindsay, G., Shubrook, K., Jones, C., Fung, M., Schaff, K., Anderson, H., Nystedt, K., and Rauw, J.
- Subjects
Population data ,sense organs ,skin and connective tissue diseases ,chemotherapy ,radiotherapy ,workload - Abstract
The years since 2005 have seen major changes in cancer treatment and significant increases in the number of anticancer drugs available. However, there are relatively few published data to reflect how those changes are affecting the activity and workload of oncology services. To explore the effects of those changes, we reviewed the population-based cancer treatment activity on Vancouver Island for the period 2010&ndash, 2015. Information about new patient referrals, radiation courses, new chemotherapy cycles commenced, total intravenous (IV) chemotherapy treatment visits, and pharmacy activity for oral anticancer drug prescriptions was obtained from BC Cancer Agency databases. During the 5-year study period, the Vancouver Island population increased by 2.8% and the number of new referrals to the BC Cancer Agency increased by 17.7%. The overall number of radiation courses increased by 6.1%. In contrast, IV chemotherapy activity increased by 52.1% for new courses commenced and by 62% for total IV chemotherapy attendances. Oral anticancer drug prescriptions rose by 22.9% during the 5-year period. Our study documents substantial recent increases in cancer therapy activity in terms of patient referrals and particularly IV chemotherapy and oral anticancer therapy. The data reported here could be of value in planning for future care provision.
- Published
- 2016
- Full Text
- View/download PDF
5. A270 DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CIRRHOSIS FROM CHRONIC HEPATITIS C VIRUS TREATED WITH DIRECT ANTIVIRAL AGENTS: THE VICTORIA EXPERIENCE
- Author
-
Trasolini, R, primary, Rauw, J, additional, Bulinckx, L, additional, and Pai, R, additional
- Published
- 2018
- Full Text
- View/download PDF
6. 269 Does the Addition of Molecular Targeted Therapy to Standard Treatments Lead to Better or Worse Outcomes Overall? A Systematic Review and Meta-analysis of EGFR-targeted Therapies Used in Combination with Standard Treatments
- Author
-
Rauw, J., primary, Ennis, M., additional, Krzyzanowska, M., additional, and Sridhar, S., additional
- Published
- 2012
- Full Text
- View/download PDF
7. A compendium of unpublished phase III clinical trials in oncology: Characteristics and impact on clinical practice.
- Author
-
Tam, V. C., primary, Tannock, I., additional, Rauw, J., additional, and Krzyzanowska, M. K., additional
- Published
- 2010
- Full Text
- View/download PDF
8. Real-world experience managing unresectable or metastatic small cell carcinoma of the prostate.
- Author
-
Ko JJ, Adams J, McMillan T, Sunderland K, Goulart J, Rauw J, and Parimi S
- Abstract
Introduction: Unresectable and metastatic small cell carcinoma of the prostate (SCPC) is a rare and aggressive disease that is under-represented in clinical trials. We carried out a retrospective chart review of metastatic or unresectable SCPC patients at British Columbia (BC) Cancer centers, studying diagnosis and treatment patterns., Methods: Drug-dispensing records from the six BC Cancer centers were obtained from 2002-2017. For each patient, information was collected on baseline information prior to therapy and for each line of treatment. Treatments at each line were compared regarding time to progression and overall survival by Kaplan-Meier curves., Results: Forty-one patients received treatment; 65.6% had metastatic disease and 61% had pure small cell carcinoma. Median time from treatment to death was 10 months (95% confidence interval [CI] 6-16). Patients with initially prostate-confined disease had a better median overall survival (mOS) of 21 months (95% CI 13-34) compared to those with initially locally advanced (mOS 19 months, 95% CI 5-37) and metastatic disease (mOS 8 months, 95% CI 6-10) (log-rank p=0.0364). All patients received either cisplatin- or carboplatin-based combination chemotherapy as the first-line treatment and 36.7% received second-line therapy. Time to second-line therapy was eight months for those who presented with metastatic SCPC, compared to 13 months for those with initial non-metastatic SCPC., Conclusions: This single-province, multi-institution cohort reports data on unresectable and metastatic SCPC and highlights the poor prognosis of this rare disease entity.
- Published
- 2022
- Full Text
- View/download PDF
9. Exercise Recommendation for People With Bone Metastases: Expert Consensus for Health Care Providers and Exercise Professionals.
- Author
-
Campbell KL, Cormie P, Weller S, Alibhai SMH, Bolam KA, Campbell A, Cheville AL, Dalzell MA, Hart NH, Higano CS, Lane K, Mansfield S, McNeely ML, Newton RU, Quist M, Rauw J, Rosenberger F, Santa Mina D, Schmitz KH, Winters-Stone KM, Wiskemann J, and Goulart J
- Subjects
- Consensus, Cross-Sectional Studies, Exercise Therapy methods, Health Personnel, Humans, Exercise physiology, Neoplasms
- Abstract
Purpose: Exercise has been underutilized in people with advanced or incurable cancer despite the potential to improve physical function and reduce psychosocial morbidity, especially for people with bone metastases because of concerns over skeletal complications. The International Bone Metastases Exercise Working Group (IBMEWG) was formed to develop best practice recommendations for exercise programming for people with bone metastases on the basis of published research, clinical experience, and expert opinion., Methods: The IBMEWG undertook sequential steps to inform the recommendations: (1) modified Delphi survey , (2) systematic review , (3) cross-sectional survey to physicians and nurse practitioners, (4) in-person meeting of IBMEWG to review evidence from steps 1-3 to develop draft recommendations, and (5) stakeholder engagement ., Results: Recommendations emerged from the contributing evidence and IBMEWG discussion for pre-exercise screening, exercise testing, exercise prescription, and monitoring of exercise response. Identification of individuals who are potentially at higher risk of exercise-related skeletal complication is a complex interplay of these factors: (1) lesion-related, (2) cancer and cancer treatment-related, and (3) the person-related. Exercise assessment and prescription requires consideration of the location and presentation of bone lesion(s) and should be delivered by qualified exercise professionals with oncology education and exercise prescription experience. Emphasis on postural alignment, controlled movement, and proper technique is essential., Conclusion: Ultimately, the perceived risk of skeletal complications should be weighed against potential health benefits on the basis of consultation between the person, health care team, and exercise professionals. These recommendations provide an initial framework to improve the integration of exercise programming into clinical care for people with bone metastases., Competing Interests: Kristin L. CampbellHonoraria: Astellas Pharma Prue CormieStock and Other Ownership Interests: Exercise Oncology EDU Pty LtdOther Relationship: EX-MED Cancer Ltd Sarah WellerResearch Funding: Astellas Pharma Shabbir M. H. AlibhaiStock and Other Ownership Interests: ResMedHonoraria: Astellas Scientific and Medical Affairs Inc Kate A. BolamStock and Other Ownership Interests: Novo Nordisk Celestia S. HiganoEmployment: CTI BioPharma Corp (I)Stock and Other Ownership Interests: CTI BioPharma Corp (I)Honoraria: Astellas PharmaConsulting or Advisory Role: Bayer, Ferring, Clovis Oncology, Blue Earth Diagnostics, Janssen, Hinova Pharmaceuticals, Pfizer, AstraZeneca, Carrick Therapeutics, Novartis, Merck Sharp & Dohme, Astellas Pharma, Myovant Sciences, Genentech, MenariniResearch Funding: Aragon Pharmaceuticals (Inst), AstraZeneca (Inst), Medivation (Inst), Emergent BioSolutions (Inst), Bayer (Inst), Pfizer (Inst), Roche (Inst), Astellas Pharma (Inst), Clovis Oncology (Inst), Ferring (Inst), eFFECTOR Therapeutics (Inst)Travel, Accommodations, Expenses: Pfizer, Janssen Oncology, Novartis, Merck Sharp & Dohme, Carrick Therapeutics Kirstin LaneStock and Other Ownership Interests: Moderna TherapeuticsTravel, Accommodations, Expenses: Astellas Pharma Robert U. NewtonHonoraria: GenesisCareResearch Funding: IpsenTravel, Accommodations, Expenses: Genesis Cancer Care Morten QuistEmployment: Zealand Pharmaceuticals (I)Honoraria: AstraZeneca Jennifer RauwHonoraria: AstraZenecaSpeakers' Bureau: GlaxoSmithKlineTravel, Accommodations, Expenses: AstraZeneca Friederike RosenbergerStock and Other Ownership Interests: BioNTech, Bristol Myers Squibb, AstraZenecaHonoraria: Bristol Myers Squibb, Hexal Kathryn H. SchmitzPatents, Royalties, Other Intellectual Property: Fees from the educational program I developed that are now offered through Klose Training and Consulting Joachim WiskemannHonoraria: Pfizer, Lilly, Novartis Jennifer GoulartResearch Funding: Astellas Pharma (Inst)No other potential conflicts of interest were reported.
- Published
- 2022
- Full Text
- View/download PDF
10. Therapeutic Implication of Genomic Landscape of Adult Metastatic Sarcoma.
- Author
-
Feng X, Pleasance E, Zhao EY, Ng T, Grewal JK, Mohammad N, Taylor SK, Simmons C, Srikanthan A, Rassekh SR, Deyell R, Rauw J, Knowling M, Khoo K, Lee U, Noonan K, Hart J, Tonseth RP, Shen Y, Titmuss E, Jones M, Bonakdar M, Reisle C, Taylor GA, Chan S, Mungall K, Chuah E, Zhao Y, Mungall A, Moore R, Lim H, Renouf DJ, Gelmon K, Yip S, Jones SJM, Marra M, and Laskin J
- Abstract
Purpose: This study investigated therapeutic potential of integrated genome and transcriptome profiling of metastatic sarcoma, a rare but extremely heterogeneous group of aggressive mesenchymal malignancies with few systemic therapeutic options., Methods: Forty-three adult patients with advanced or metastatic non-GI stromal tumor sarcomas of various histology subtypes who were enrolled in the Personalized OncoGenomics program at BC Cancer were included in this study. Fresh tumor tissues along with blood samples underwent whole-genome and transcriptome sequencing., Results: The most frequent genomic alterations in this cohort are large-scale structural variation and somatic copy number variation. Outlier RNA expression as well as somatic copy number variations, structural variations, and small mutations together suggest the presence of one or more potential therapeutic targets in the majority of patients in our cohort. Point mutations or deletions in known targetable cancer genes are rare; for example, tuberous sclerosis complex 2 provides a rationale for targeting the mammalian target of rapamycin pathway, resulting in a few patients with exceptional clinical benefit from everolimus. In addition, we observed recurrent 17p11-12 amplifications, which seem to be a sarcoma-specific event. This may suggest that this region harbors an oncogene(s) that is significant for sarcoma tumorigenesis. Furthermore, some sarcoma tumors carrying a distinct mutational signature suggestive of homologous recombination deficiency seem to demonstrate sensitivity to double-strand DNA-damaging agents., Conclusion: Integrated large-scale genomic analysis may provide insights into potential therapeutic targets as well as novel biologic features of metastatic sarcomas that could fuel future experimental and clinical research and help design biomarker-driven basket clinical trials for novel therapeutic strategies.
- Published
- 2019
- Full Text
- View/download PDF
11. A case of intraplacental gestational choriocarcinoma; characterised by the methylation pattern of the early placenta and an absence of driver mutations.
- Author
-
Savage P, Monk D, Hernandez Mora JR, van der Westhuizen N, Rauw J, Tinker A, Robinson W, Song Q, Seckl MJ, and Fisher RA
- Subjects
- Adult, CpG Islands genetics, Epigenesis, Genetic genetics, Female, Follow-Up Studies, Humans, Microsatellite Repeats genetics, Phenotype, Pregnancy, Trophoblasts pathology, Whole Genome Sequencing, Choriocarcinoma genetics, DNA Methylation genetics, Gestational Trophoblastic Disease genetics, Mutation genetics, Placenta pathology, Uterine Neoplasms genetics
- Abstract
Background: Gestational choriocarcinoma is a rare malignancy believed to arise from the trophoblast cells of the placenta. Despite the frequently aggressive clinical nature, choriocarcinoma has been routinely curable with cytotoxic chemotherapy for over 50 years. To date little is known regarding the route to oncogenesis in this malignancy., Methods: In a case of intraplacental choriocarcinoma, we have performed detailed genetic studies including microsatellite analysis, whole genome sequencing (WGS) and methylation analysis of the tumour and surrounding mature placenta., Results: The results of the WGS sequencing indicated a very low level of mutation and the absence of any driver mutations or oncogene activity in the tumour. The methylation analysis identified a distinctly different profile in the tumour from that of the mature placenta. Comparison with a panel of reference methylation profiles from different stages of placental development indicated that the tumour segregated with the first trimester samples., Conclusions: These findings suggest that gestational choriocarcinoma is likely to arise as a result of aberrations of methylation during development, rather than from DNA mutations. The results support the hypothesis that gestational choriocarcinoma arises from a normally transient early trophoblast cell. At this point in development this cell naturally has a phenotype of rapid division, tissue invasion and sensitivity to DNA damaging chemotherapy that is very similar to that of the mature choriocarcinoma cell.
- Published
- 2019
- Full Text
- View/download PDF
12. Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma.
- Author
-
Rauw J, Ahmed S, and Petrella T
- Subjects
- Adult, Female, Humans, Interferon alpha-2, Melanoma secondary, Prognosis, Recombinant Proteins adverse effects, Cardiac Tamponade chemically induced, Interferon-alpha adverse effects, Melanoma drug therapy, Pericardial Effusion chemically induced
- Abstract
Regional Metastatic Melanoma has a relatively high mortality rate. Adjuvant interferon-alpha (IFN-α) has been shown to improve disease-free survival, post-resection. Cardiotoxicity associated with IFN-α use has been described previously in the literature, but here we describe the first case of pericardial effusion with cardiac tamponade secondary to IFN-α 2b treatment of melanoma. Clinicians should be aware of this potentially lethal complication and the possible acuity of its onset.
- Published
- 2012
- Full Text
- View/download PDF
13. Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice.
- Author
-
Tam VC, Tannock IF, Massey C, Rauw J, and Krzyzanowska MK
- Subjects
- Humans, Publishing, Randomized Controlled Trials as Topic, Societies, Medical, Clinical Trials, Phase III as Topic, Neoplasms therapy
- Abstract
Purpose: Many phase III trials presented at annual meetings of the American Society of Clinical Oncology (ASCO) remain unpublished. The results of these unpublished trials, if more generally known, might have an impact on clinical practice., Methods: Abstracts of large phase III trials evaluating systemic cancer treatment were identified from conference proceedings of the 1989 to 2003 ASCO annual meetings. PubMed, Medline, and Embase were searched for corresponding publications. A compendium of unpublished phase III trials was assembled. Clinical significance of nonpublication was determined by disease site-specific oncology experts from two academic cancer centers in Canada., Results: A total of 709 phase III trials were identified of which 66 (9.3%) remain without a subsequent publication at a minimum of 6.5 years of follow-up and 94 (13%) were published after a delay of ≥ 5 years from their initial presentation. Of the unpublished trials, 48% were presented as oral sessions at an ASCO meeting, and 71% of the abstracts reported negative results. The experts judged that 70% of the unpublished trials addressed an important question and 59% might have had clinical impact if their results had been published promptly., Conclusion: A substantial number of cancer clinical trials with potential influence on clinical practice remain unpublished and many other trials are published after a substantial delay. Nonpublication of clinical trials breaks an implicit contract with participants, institutional review boards, and sponsors.
- Published
- 2011
- Full Text
- View/download PDF
14. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma.
- Author
-
Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, and Stewart AK
- Subjects
- Apoptosis Regulatory Proteins drug effects, Apoptosis Regulatory Proteins genetics, Bcl-2-Like Protein 11, Caspase 3 drug effects, Caspase 3 metabolism, Cell Line, Tumor, Cytochromes c drug effects, Cytochromes c metabolism, Drug Screening Assays, Antitumor, Humans, Indoles, Membrane Proteins drug effects, Membrane Proteins genetics, Myeloid Cell Leukemia Sequence 1 Protein, Neoplasm Proteins metabolism, Protein Binding drug effects, Proto-Oncogene Proteins drug effects, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins c-bcl-2 metabolism, Pyrroles therapeutic use, Up-Regulation drug effects, bcl-2 Homologous Antagonist-Killer Protein metabolism, Multiple Myeloma drug therapy, Pyrroles pharmacology
- Abstract
Bcl family members Bcl-2, Bcl-x(L), and Mcl-1, are frequently expressed and implicated in the survival of myeloma cells. Obatoclax (GX015-070) is a novel, small-molecule antagonist of the BH3-binding groove of the Bcl family of proteins. We show that GX015-070 inhibits the binding of Bak to Mcl-1, up-regulates Bim, induces cytochrome c release, and activates capase-3 in human myeloma cell lines (HMCLs), confirming the predicted mechanism of action. Consequently, GX015-070 potently inhibited the viability of 15 of 16 HMCLs (mean IC(50) of 246 nM), including those resistant to melphalan and dexamethasone. In combination studies, GX015-070 enhanced the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. Sensitivity to GX015-070 correlated with the absence or near absence of Bcl-x(L). Coculture with interleukin-6 or adherence to bone marrow stroma conferred modest resistance; however, it did not overcome GX015-070-induced cytotoxicity. Of importance, GX015-070 as a single agent induced potent cytotoxic responses against patient-derived tumor cells. GX015-070 inhibited normal bone marrow-derived colony formation; however, cytotoxicity to human blood lymphocytes was not observed. Taken together, these studies describe a novel BH3 mimic with selectivity for Mcl-1, and support the therapeutic application of GX015-070 for diverse neoplasias including multiple myeloma.
- Published
- 2007
- Full Text
- View/download PDF
15. Ran modulates spindle assembly by regulating a subset of TPX2 and Kid activities including Aurora A activation.
- Author
-
Trieselmann N, Armstrong S, Rauw J, and Wilde A
- Subjects
- Active Transport, Cell Nucleus, Aurora Kinases, Cell Nucleus, Enzyme Activation physiology, Female, HeLa Cells, Humans, Microtubules metabolism, Protein Binding, Protein Serine-Threonine Kinases, Xenopus Proteins, Cell Cycle Proteins metabolism, DNA-Binding Proteins metabolism, Kinesins metabolism, Microtubule-Associated Proteins metabolism, Neoplasm Proteins metabolism, Nuclear Proteins metabolism, Phosphoproteins metabolism, Protein Kinases metabolism, Spindle Apparatus metabolism, ran GTP-Binding Protein metabolism
- Abstract
Ran, a GTPase in the Ras superfamily, is proposed to be a spatial regulator of microtubule spindle assembly by maintaining key spindle assembly factors in an active state close to chromatin. RanGTP is hypothesized to maintain the spindle assembly factors in the active state by binding to importin beta, part of the nuclear transport receptor complex, thereby preventing the inhibitory binding of the nuclear transport receptors to spindle assembly factors. To directly test this hypothesis, two putative downstream targets of the Ran spindle assembly pathway, TPX2, a protein required for correct spindle assembly and Kid, a chromokinesin involved in chromosome arm orientation on the spindle, were analyzed to determine if their direct binding to nuclear transport receptors inhibited their function. In the amino-terminal domain of TPX2 we identified nuclear targeting information, microtubule-binding and Aurora A binding activities. Nuclear transport receptor binding to TPX2 inhibited Aurora A binding activity but not the microtubule-binding activity of TPX2. Inhibition of the interaction between TPX2 and Aurora A prevented Aurora A activation and recruitment to microtubules. In addition we identified nuclear targeting information in both the amino-terminal microtubule-binding domain and the carboxy-terminal DNA binding domain of Kid. However, the binding of nuclear transport receptors to Kid only inhibited the microtubule-binding activity of Kid. Therefore, by regulating a subset of TPX2 and Kid activities, Ran modulates at least two processes involved in spindle assembly.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.